Tempus AI (TEM) announced the clinical launch of its Immune Profile Score (IPS) algorithmic test. IPS, which is now available for clinicians to order, is a multimodal biomarker that can be used as a ...

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the clinical launch of its ...

To test IPS performance, we constructed a test bed that offered traffic at multigigabit rates (see diagram). Two Spirent ThreatEx 2500 appliances offered various exploits, while two Spirent Avalanche ...

A comprehensive lab evaluation of six intrusion-prevention systems that automatically block attacks suggests IPS is ready for enterprise use despite concerns that false positives will lead to the ...